UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2020

(Commission File No. 001-37518)

 

Benitec Biopharma Limited

(Translation of registrant’s name into English)

 

Level 14, 114 William St, Melbourne, VIC, 3000

Australia

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

    Yes      No  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

    Yes      No  

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes      No  

 

 

 

 


 

EXHIBIT INDEX

 

Exhibit

 

Description

99.1

 

 

Appendix 3Y

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

Benitec Biopharma Limited

 

By:

/s/ Megan Boston

Name:

Megan Boston

Title:

Executive Director

Date: March 30, 2020

 

 

bntc-ex99_6.htm

Appendix 3Y

Change of Director’s Interest Notice

 

 

Rule 3.19A.2

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available.  Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01  Amended 01/01/11

 

Name of entity         Benitec Biopharma Limited

ABN                            64 068 943 662

 

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.  

 

Name of Director

Peter Damian Francis

Date of last notice

4 June 2018

 

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest

Direct and indirect

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 

Francis Family Superannuation Fund

Date of change

27 March 2020

No. of securities held prior to change

Direct

90,000 fully paid ordinary shares (FPOS)

 

Indirect

546,261 FPOS

Class

As above

Number acquired

875,000 FPOS

Number disposed

None

Value/Consideration

Note: If consideration is non-cash, provide details and estimated valuation

 

$27,157.55

 

+ See chapter 19 for defined terms.

 

01/01/2011Appendix 3Y  Page 1

 


Appendix 3Y

Change of Director’s Interest Notice

 

 

No. of securities held after change

Direct

90,000 FPOS

 

Indirect

1,421,261 FPOS

Nature of change

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

On-market purchase

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract

Not applicable.

Nature of interest

 

 

 

Name of registered holder

(if issued securities)

 

 

Date of change

 

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 

 

Interest acquired

 

Interest disposed

 

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 

 

Interest after change

 

 

Part 3 – +Closed period

 

 

+ See chapter 19 for defined terms.

 

Appendix 3Y Page 201/01/2011

 


Appendix 3Y

Change of Director’s Interest Notice

 

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?

No, the securities were not acquired during a closed period.

 

Notwithstanding this, the Company’s Securities Trading Policy requires that directors seek written clearance before trading at any time. Written clearance was sought and obtained before trading.

If so, was prior written clearance provided to allow the trade to proceed during this period?

As above.

If prior written clearance was provided, on what date was this provided?

Written clearance was provided on 27 March 2020.

 

 

 

 

+ See chapter 19 for defined terms.

 

01/01/2011

Appendix 3Y  Page 3